IL6 and esophageal squamous cell carcinoma: Compelling evidence suggests that IL-6 derived from CAFs mediates therapeutic resistance, including chemoresistance by upregulating CXCR7 expression via STAT3/NF-κb pathway in ESCC [62], and IL-6 blockade improves checkpoint blockade therapy and promotes tumor immunity [63].